Increase in LDL may not always be associated with increase in CV risk

3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Allyson Morton

ISA2015 | Clinical Breakthroughs Allyson Morton (Boston, USA) presented a follow-up study of the EVOLVE trial, which showed that omega-3 carboxylic acid treatment reduced apoCIII levels in whole plasma, and in HDL and LDL. LDL levels without apoCIII were reduced, which has a weak relation to CV risk.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.